Literature DB >> 6932925

Marker proteins as indicators of tumour response to therapy.

K D Bagshawe.   

Abstract

Serological markers which are secreted products of tumour cells have the potential to provide an indicator of viable tumour mass. In practice their ability to do this depends on a variety of factors which include specificity, mode of metabolism and concentration in relation to viable tumour bulk and assay sensitivity. In general, eutopic products have proved more useful than ectopic products which with few exceptions tend to be produced in only small concentrations even in advanced disease states. Human chorionic gonadotrophin produced by choriocarcinoma remains the most effective marker for any human tumour. For more than 20 years this marker has provided a reliable guide to the course of the disease and the response to therapy. There is a clear distinction between therapy which is ineffective and that which is effective in terms of marker concentration. The limitations of this substance and other tumour markers as indicators of response to therapy will be discussed.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6932925      PMCID: PMC2149257     

Source DB:  PubMed          Journal:  Br J Cancer Suppl        ISSN: 0306-9443


  3 in total

1.  Computer controlled automated radioimmunoassay.

Authors:  K D Bagshawe
Journal:  Lab Pract       Date:  1975-09

2.  Immunodiagnosis and monitoring of gonadotrophin-producing metastases in the central nervous system.

Authors:  K D Bagshawe; S Harland
Journal:  Cancer       Date:  1976-07       Impact factor: 6.860

3.  Risk and prognostic factors in trophoblastic neoplasia.

Authors:  K D Bagshawe
Journal:  Cancer       Date:  1976-09       Impact factor: 6.860

  3 in total
  3 in total

Review 1.  Predictive tests in cancer chemotherapy. A reappraisal.

Authors:  R Osieka; S Seeber; C G Schmidt
Journal:  Klin Wochenschr       Date:  1984-03-01

2.  Serum levels of six tumor markers in patients with benign and malignant gynecological disease.

Authors:  I Fukazawa; N Inaba; Y Ota; N Sato; S Shirotake; H Iwasawa; T Sato; H Takamizawa; B Wiklund
Journal:  Arch Gynecol Obstet       Date:  1988       Impact factor: 2.344

3.  The potential of carboxypeptidase G2: antibody conjugates as anti-tumour agents. II. In vivo localising and clearance properties in a choriocarcinoma model.

Authors:  R G Melton; F Searle; R F Sherwood; K D Bagshawe; J A Boden
Journal:  Br J Cancer       Date:  1990-03       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.